Risks to Intellectual Property Protection Related to Patent Grant, Maintenance and Competition
First written in FY2016. 6 of 9 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2020: 4 of 43 companies on the "Worse" side.
64 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「IDO/TDO inhibitor IDO/TDO inhibitor (Note) 3 2019／078246 Granted in Japan and the United States.」
The company continues to disclose the Japanese and U.S. patents for the IDO/TDO inhibitor and U.S. patents for CBT005, among others, along with the risks that patents may not be granted or maintained and may be rendered ineffective by competitors. - FY2025MitigatedAnnual report
「CBT005 Phosphatidylserine complex Our company 2023/126885 Granted in the United States. IDO/TDO inhibitors IDO/TDO inhibitors (Note) 2 2019/078246 Granted in Japan and the United States.」
The company reported that the US patent for CBT005 had been granted and that the IDO/TDO inhibitor patent had also been granted in the United States in addition to Japan, indicating progress in protecting the intellectual property of its follow-on pipeline. - FY2024RestatedAnnual report
「In addition, there is always a risk that our patents could be rendered obsolete or ineffective by superior development capabilities exceeding those of our research and development activities.」
In addition to patent grant and maintenance, the company continues to disclose the risk that intellectual property may be rendered obsolete or ineffective by competing research and development. - FY2023MitigatedAnnual report
「IDO/TDO inhibitors IDO/TDO inhibitors (Note) 2 2019/078246 Granted in Japan.」
The company reported that a shared patent relating to IDO/TDO inhibitors had been granted in Japan, indicating concrete progress in protecting the intellectual property of this candidate. - FY2022RestatedAnnual report
「In addition, there is always a risk that our patents could be rendered obsolete or ineffective by superior development capabilities exceeding those of our research and development activities.」
In addition to patent grant and maintenance, the company continues to disclose the risk that intellectual property may be rendered obsolete or ineffective by competing research and development. - FY2021RestatedAnnual report
「Although we conduct sufficient investigations into patentability and other matters when filing each patent application in progress, there is no guarantee that all patent applications will result in granted patents.」
The company continues to disclose the possibility that patents may not be granted or maintained and that competing technologies may render them obsolete or ineffective. - FY2020RestatedAnnual report
「Although we conduct sufficient investigations into patentability and other matters when filing each patent application in progress, there is no guarantee that all patent applications will result in granted patents.」
The company continues to disclose the possibility that patents may not be granted or maintained and that competing technologies may render them obsolete or ineffective. - FY2017RestatedAnnual report
「The primary patent for CBP501, a composition-of-matter patent, has international publication number 2003/059942 and expires in the United States on 17 January 2023.」
The company continues to disclose the status and expiry date of its primary patents, as well as the possibility that applications may not result in granted patents or that competing technologies may render them ineffective. - FY2016First statedAnnual report
「The primary patent for CBP501, a composition-of-matter patent, has international publication number 2003/059942 and expires in the United States on 17 January 2023. However, because a patent-term extension system exists for pharmaceuticals, the above expiry date may be extended.」
The company discloses the patent expiry date, the possibility that applications may not result in granted patents, and the possibility that competing technologies may render the patents obsolete or ineffective.